Archive for July, 2019

Zhejiang takes the lead in implementing DRGs payment

July 19th, 2019 | by

On July 18th, the Zhejiang Medical Insurance Bureau issued the “Opinions on Promoting the Reform of Basic Medical Insurance Payment Methods for Medical Communities in Zhejiang Province,” and plans to implement multiple and composite medical insurance payment methods under total budget management. For inpatient medical services, the payment is mainly based on the DRGs (Diagnosis-Related Groups) system. For long-term and chronic disease inpatient medical services, the “daily payment for each sickbed” will be gradually promoted. For outpatient medical services, the “per-head payment” will be implemented, which also combines the “Contracted Family Doctor Services”.


来源:医药网  2019.07.19


“Guideline” for “Internet+Health Care” in Shandong province released

July 15th, 2019 | by

On July 11th, the Shandong Provincial Government issued the “Notification on the Construction Plan for Promoting a Demonstration Province of ‘Internet+Health Care’ from 2019 to 2020.” The “Notification” stipulates that to achieve the real-time exchange and sharing of medical data, the construction of a “traceability system of drugs,” a “pre-warning and detecting system of medicines in short supply,” and a “prescription circulation platform” should be promoted. The “Notification” indicates that the construction of “Internet Hospitals” based on medical institutes is encouraged, and the “consulting or prescribing medicine over the internet” should be widely implemented in Shandong province from 2020.

山东“互联网+医疗健康”的路线图, 来了!

来源:医药网 2019.07.15


“List of National Intensive Monitoring Drug” is released

July 2nd, 2019 | by

On July 1st, the Medical Administration Bureau of the National Health Commission issued the “Notification on printing the first List of National Intensive Monitoring Drug (Chemicals and Biological Products),” 20 drugs were selected in the “List.” The “Notification” stipulates that all provinces should form a list of provincial intensive monitoring drug on the basis of the national “List” and publish it for use by various medical institutions. All medical institutions should establish a regulatory system for monitoring drugs and strengthen the management of clinical applications of them. At the same time, the prescription management of drugs outside the “List” should also be strengthened.


来源:医药网 2019.07.02

核心提示:7月1日,国家卫健委医政医管局发布了《关于印发第一批国家重点监控合理用药药品目录(化药及生物制品)的通知》,共20个药品入选。 《通知》要求, 各省应在《目录》基础上形成省级重点监控合理用药药品目录并公布,以供各类医疗机构参考;各医疗机构要建立重点监控合理用药药品管理制度,加强目录内药品临床应用的全程管理;同时,还应加强目录外药品的处方管理。

“Drug Evaluation Report in 2018” is released

July 1st, 2019 | by

On July 1st, the National Medical Products Administration(NMPA) issued the “Drug Evaluation Report in 2018.” The “Report” shows that the Drug Evaluation Centre of the NMPA reviewed and approved 106 new drugs in 2018. Although the number of applications for registration of new drugs has increased by 47%, the evaluation time has been reduced significantly in comparison to 2017. Benefiting from the accelerated drug evaluation reforms, the number of applications for registration of innovative drugs has increased significantly in 2018, of which 85% were from domestic companies. At the same time, in order to improve the quality of generic drugs, the Drug Evaluation Centre has made every effort to promote the “Quality Consistency Evaluation for Generic Drugs,” and there were eight batches of generic drugs that are involved in comparison to 2018.


来源:中国医药报 2019.07.01